PM Modi paid his visit to Pune-based Serum Institute of India and reviewed the manufacturing process of COVID-19 vaccine. He interacted with scientists at the SII and went around the facility, taking stock of vaccine development work

PM Modi landed at Hakimpet Air Force station near here at around 1 pm,as part of his three-city tour to take the stock of COVID-19 vaccine development

PM Modi took stock of the work being done so far on the development of coronavirus vaccine at the Zydus Cadila research centre

Prime Minister Narendra Modi's visit to these facilities and discussions with the scientists are to help him get a first-hand perspective of the preparations, challenges and roadmap in India's vaccination plans

After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon

Indian drug regulator may provide an emergency approval to AstraZeneca's COVID-19 vaccine by end-December or early January 21, says Nomura

A blow-by-blow account of how Indian vaccines are being readied

Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first

The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine

Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public

The Prime Minister is expected to hold two back-to-back meetings, one with those states with high caseloads and another related to vaccine distribution strategy.

Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose

\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19

Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week

The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India

Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year

As per Anthony Fauchi, the Pfizer's vaccine distribution process in the US will start in December. This, he said, will also help reduce the daily spike in coronavirus cases, which reached 1.9 lakh this week

Nirmala Sitharaman press conference: The minister said that the Rs 900 crore funding to the Department of Biotechnology will be for research purposes only

COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)